Renal cancer: new models and approach for personalizing therapy.

ABSTRACT:

Background

Clear cell RCC (ccRCC) accounts for approximately 75% of the renal cancer cases. Surgery treatment seems to be the best efficacious approach for the majority of patients. However, a consistent fraction (30%) of cases progress after surgery with curative intent. It is currently largely debated the use of adjuvant therapy for high-risk patients and the clinical and molecular parameters for stratifying beneficiary categories. In addition, the treatment of advanced forms lacks reliable driver biomarkers for the appropriated therapeutic choice. Thus, renal cancer patient management urges predictive molecular indicators and models for therapy-decision making.

Methods

Here, we developed and optimized new models and tools for ameliorating renal cancer patient management.

SUBMITTER: di Martino S 

PROVIDER: S-EPMC6126022 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature